» Articles » PMID: 32834785

Antimicrobial Stewardship at the Core of COVID-19 Response Efforts: Implications for Sustaining and Building Programs

Overview
Date 2020 Aug 25
PMID 32834785
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

We describe traditional antimicrobial stewardship program (ASP) activities with a discussion of how these activities can be refocused in the setting of the COVID-19 pandemic. Additionally, we discuss possible adverse consequences of ASP attention diversion on COVID-19 response efforts and overall implications for future pandemic planning. We also discuss ASP in collaboration with other groups within health systems and how COVID-19 may affect these relationships long term. Despite the paucity of literature on Antimicrobial Stewardship and COVID-19, the potential contributions of ASPs during a pandemic are numerous. ASPs can develop strategies to identify patients with COVID-19-like-illness; this is particularly useful when these patients are missed at the time of health system entry. ASPs can also play a critical role in the management of potential drug shortages, developing local treatment guidelines, optimizing the use of antibiotics, and in the diagnostic stewardship of COVID-19 testing, among other roles. Importantly, it is often difficult to ascertain whether critically ill patients who are hospitalized with COVID-19 have concurrent or secondary bacterial infections-ASPs are ideally situated to help optimize antimicrobial use for these patients via a variety of mechanisms. ASPs are uniquely positioned to aid in pandemic response planning and relief efforts. ASPs are already integrated into health systems and play a key role in optimizing antimicrobial prescribing. As ASPs assist in COVID-19 response, understanding the role of ASPs in pandemic relief efforts may mitigate damage from future outbreaks.

Citing Articles

Antimicrobial use before and during COVID-19: data from 108 Veterans Affairs medical centers.

Goetz M, Willson T, Rubin M, Stevens V, Graber C Antimicrob Steward Healthc Epidemiol. 2025; 4(1):e109.

PMID: 39823121 PMC: 11736461. DOI: 10.1017/ash.2024.352.


COVID-19 therapeutics: stewardship in England and considerations for antimicrobial resistance.

Bou-Antoun S, Rokadiya S, Ashiru-Oredope D, Demirjian A, Sherwood E, Ellaby N J Antimicrob Chemother. 2023; 78(Suppl 2):ii37-ii42.

PMID: 37995354 PMC: 10666993. DOI: 10.1093/jac/dkad314.


Antibiotic Use Among Hospitalized Patients With COVID-19 in the United States, March 2020-June 2022.

Kim C, Wolford H, Baggs J, Reddy S, Hicks L, Neuhauser M Open Forum Infect Dis. 2023; 10(11):ofad503.

PMID: 37942462 PMC: 10629359. DOI: 10.1093/ofid/ofad503.


Increased Incidence and Risk Factors of Infections by Extended-Spectrum β-Lactamase-Producing Enterobacterales During the COVID-19 Pandemic: A Retrospective Case-Control Study.

Geng Y, Li F, Chen C, Liu Z, Ma X, Su X Infect Drug Resist. 2023; 16:4707-4716.

PMID: 37492798 PMC: 10364815. DOI: 10.2147/IDR.S421240.


Pharmacist-driven antimicrobial stewardship interventions in patients with COVID-19: a scoping review.

Nasr Z, Elamin W, Basil M, Eljaaly K Int J Clin Pharm. 2023; 45(3):613-621.

PMID: 37162655 PMC: 10171144. DOI: 10.1007/s11096-023-01574-0.


References
1.
Stevens R, Estes L, Rivera C . Practical implementation of COVID-19 patient flags into an antimicrobial stewardship program's prospective review. Infect Control Hosp Epidemiol. 2020; 41(9):1108-1110. PMC: 7184145. DOI: 10.1017/ice.2020.133. View

2.
McCreary E, Pogue J . Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options. Open Forum Infect Dis. 2020; 7(4):ofaa105. PMC: 7144823. DOI: 10.1093/ofid/ofaa105. View

3.
Dellit T, Owens R, McGowan Jr J, Gerding D, Weinstein R, Burke J . Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2006; 44(2):159-77. DOI: 10.1086/510393. View

4.
Bremmer D, Trienski T, Walsh T, Moffa M . Role of Technology in Antimicrobial Stewardship. Med Clin North Am. 2018; 102(5):955-963. DOI: 10.1016/j.mcna.2018.05.007. View

5.
Cyriac J, James E . Switch over from intravenous to oral therapy: A concise overview. J Pharmacol Pharmacother. 2014; 5(2):83-7. PMC: 4008927. DOI: 10.4103/0976-500X.130042. View